Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

NCT06780917 · tracked via the Priya Life Science Canada tracker

Sponsor

Centre for Addiction and Mental Health

Phase

Observational

Started

2025-01-13

Last updated

2026-03-10

Condition(s) studied

Mild Cognitive Impairment (MCI)Major Depressive Disorder, RemittedHealthy Controls Group - Age and Sex-matched

Study summary

The goal of this observational study is to validate the Creyos online cognitive assessment platform in individuals with mild cognitive impairment, or remitted major depressive disorder. The main objectives of this research are:

1. To confirm the feasibility of administering the Creyos cognitive battery to older adults with Mild Cognitive Impairment MCI) or Major Depressive Disorder in remission (rMDD).
2. To determine whether the Creyos battery can detect changes in cognition that are predictive of changes on paper-and-pencil neuropsychological testing ("gold standard") over up to five years.

Participants will complete both in-person neuropsychological testing yearly as well as the Creyos online battery quarterly for up to 5 years, to allow us to compare performance on these two batteries over time.

Eligibility

Sex

ALL

Min age

60 Years

Max age

—

Healthy volunteers

Accepted

General Inclusion Criteria: * Ability to read and communicate in English * Availability of a study partner who has regular contact with the participant General Exclusion Criteria: * Lifetime DSM 5 diagnosis of schizophrenia, bipolar disorder, or OCD * DSM 5 diagnosis of alcohol or other substance use disorder within the past 12 months * High risk for suicide * Significant neurological conditions (e.g. stroke, seizure disorder, MS) * Unstable medical illnesses (e.g. uncontrolled diabetes mellitus or hypertension) * Taking anticonvulsants or other psychotropic medication that may interfere with cognitive testing that cannot be safely tapered and discontinued * Current depressive symptoms defined as a MADRS score of 10 or above Specific Eligibility Criteria for the MCI Group: Inclusion: * Aged 60 or older * Meets DSM 5 criteria for Minor Neurocognitive Disorder ("MCI") Exclusion: * Having taken a cognitive enhancer within the past 6 weeks Specific Eligibility Criteria for the rMDD Group: Inclusion: * Aged 65 or older * Meets DSM 5 criteria for one or more major depressive episode(s) (MDE) during their adult life (i.e. 18 years of age or older) with: (a) an offset of 2 months to 5 years from the screening visit date, or (b) an offset of 5 years or more, with at least one MDE receiving medical attention (e.g. previously been on an antidepressant, saw a psychiatrist, primary care physician, or had a previous hospitalization Exclusion: * Having taken a cognitive enhancer within the past 6 weeks * Having received electroconvulsive therapy (ECT) within 6 months of baseline neuropsychological testing Specific Eligibility Criteria for the Control Group: Inclusion: * Aged 60 or older Exclusion: * Meets DSM 5 criteria for MDD at anytime during their lifetime * Meets DSM 5 criteria for Minor Neurocognitive Disorder ("MCI")

Primary outcome measure(s)

Feasibility of Creyos Battery Administration — Upon completion of the Creyos online cognitive platform, approximately every three months, for up to 5 years
To determine the feasibility of administering the Creyos online cognitive platform in individuals with MCI and major depressive disorder in remission, participants will complete two questionnaires after every completion of the Creyos battery. Participants will be asked to complete the System Usability Scale (10 items). Scores on the System Usability Scale range from 0 to 100, with higher scores indicating greater usability. We will look at the total score to determine how easy the participants find the Creyos online cognitive platform to use, and if usability increases with exposure to the platform.
Feasibility of the Creyos Battery — Upon completion of the Creyos online cognitive platform, approximately every three months, for up to 5 years
To determine the feasibility of administering the Creyos online cognitive platform in individuals with MCI and major depressive disorder in remission, participants will complete two questionnaires after every completion of the Creyos battery. Participants will be asked to complete the User Burden Scale (20 items). Scores on the User Burden Scale range from 0 to 80, with higher scores indicating greater user burden. We will look at the total score to determine how easy the participants find the Creyos online cognitive platform to use, and if usability increases with exposure to the platform.
Validity of the Creyos Platform — In-person testing is completed yearly, and the Creyos online battery is complete quarterly, for up to 5 years
To determine the validity of the Creyos online platform, we will compare the single test scores, domain composite scores and global composite scores between the in-person paper-and-pencil neuropsychological tests ("gold standard") and the Creyos online battery.

Trial sites (3)

Facility	City	Region	Status
St. Michael's Hospital	Toronto	Ontario	Recruiting
University Health Network	Toronto	Ontario	Recruiting
Centre for Addiction and Mental Health	Toronto	Ontario	Recruiting

More Centre for Addiction and Mental Health trials in Canada

Matching Assessment and Treatment for Children With Disruptive Behaviour and Their Parents Recruiting

HABITS Study (Helping Addiction by Individualized Therapeutic Stimulation): Pilot Trial of Deep Brain Stimulation Guided By Stereoelectroencephalography for Treatment-Refractory Substance Use Disorders Recruiting

Dialectical Behavior Therapy for Youth With and/or at Familial Risk for Bipolar Disorder Recruiting

Transcranial Magnetic Stimulation for Nicotine Dependence: An Effectiveness-Implementation Trial Recruiting

Enhancing Frontal Lobes Plasticity in Mild Cognitive Impairment Active, not recruiting

Other trials for the same condition

Effect of Accelerated Neuromodulation of Anterior Cingulate Cortex to Enhance Cognition in Older Adults With Mild Memory Problems Recruiting

TACS to Engage Theta-Gamma Coupling and Enhance Working Memory in Patients With MCI (tACS-MCI) Recruiting

Comprehensive Assessment of Neurodegeneration and Dementia Recruiting

CPAP Randomized Controlled Trial Starting soon

Creatine and Resistance Training in Older Adults With Mild Cognitive Impairment Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06780917 on ClinicalTrials.gov ↗ ← All trials in Canada